9 Questions
What percentage of patients on immunosuppression + RASi reached clinical remission at trial endpoint?
17%
How many patients taking immunosuppression had an eGFR decrease of ≥15 mL/min/1.73 m2 at trial endpoint?
22
What adverse events were predominantly associated with immunosuppression?
Gastrointestinal and respiratory tract infections
What was the primary renal outcome percentage for patients taking methylprednisolone at trial endpoint?
28.8%
What risk was associated with methylprednisolone compared to placebo?
Increased risk of severe adverse events
How many patients on methylprednisolone developed a severe infection requiring hospitalization despite antibiotic prophylaxis within the first 12 weeks of therapy?
5
What was the predominant ethnicity of the patient population in the testing for methylprednisolone?
Asian
Was proteinuria reduction still apparent in participants 36 months after randomization?
No, it was no longer apparent
Did many participants continue to gain kidney function over time?
No, they continued to lose kidney function
Learn about the comparison of immunosuppression and RASi (renin-angiotensin system inhibitors) treatments for IgA nephropathy based on the trial results. Explore the differences in clinical remission rates, eGFR decrease, adverse events, infections, and other associated risks.
Make Your Own Quizzes and Flashcards
Convert your notes into interactive study material.
Get started for free
